Oxford BioMedica has indicated it could consider a private equity takeover under the right circumstances, even after rejecting multiple unsolicited approaches from Sweden’s EQT earlier this year, according to a report by the Financial Times citing comments from its chief executive.
Frank Mathias, who has led the UK-listed cell and gene therapy company since 2023, said the group is open to evaluating bids that align with its long-term strategy and could support faster growth, though any offer wou...
Continue Reading
Sign up for FREE to read the full article and access 129K+ alternative investment headlines.
Alternative Investment News